Menu Search
Equities

Qyuns Therapeutics Co Ltd

2509:HKG.HZ

Qyuns Therapeutics Co Ltd

Actions
  • Price (HKD)12.00
  • Today's Change-1.00 / -7.69%
  • Shares traded22.80k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 02:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qyuns Therapeutics Co Ltd is a China-based company mainly engaged in biopharmaceuticals. The Company is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The Company's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The Company is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The Company's core products include QX002N and QX005N.

  • Revenue in HKD (TTM)48.31m
  • Net income in HKD-453.64m
  • Incorporated2015
  • Employees325.00
  • Location
    Qyuns Therapeutics Co LtdRoom 1310Building 1, No. 907 Yaocheng AvenueTAIZHOU ChinaCHN
  • Phone+86 52 380276311
  • Websitehttp://www.qyuns.net/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.